论文部分内容阅读
目的探讨缬沙坦对心力衰竭患者的疗效及可能机制。方法本研究将入选的102例心力衰竭患者随机分为3组。常规对照组30例,给予利尿、扩血管等常规抗心衰治疗。ACEI组36例,在常规抗心衰治疗基础上,给予卡托普利75mg/d。ARB组36例在常规抗心衰治疗基础上,给予缬沙坦80mg/d。用药前及用药后2个月彩色多普勒仪检测EF值及抽取患者晨空腹静脉血检测。结果各组治疗前后血钾、血肌酐变化无统计学意义。ACEI组与ARB组治疗前后CRP下降,ARB组更明显(P<0.05)、ACEI组与ARB组治疗前后EF升高,ARB组明显(P<0.05)。结论缬沙坦抑制肾素—血管紧张素—醛固酮系统(RAAS)的过度激活,改善心功能。
Objective To investigate the efficacy and possible mechanism of valsartan in patients with heart failure. Methods In this study, 102 selected patients with heart failure were randomly divided into three groups. Routine control group of 30 cases, given diuretic, vasodilators and other conventional anti-heart failure treatment. ACEI group of 36 cases, in the conventional anti-heart failure treatment based on the given captopril 75mg / d. 36 cases of ARB group were given valsartan 80mg / d on the basis of routine anti-heart failure treatment. Before treatment and 2 months after treatment, the color Doppler echocardiography was used to detect the EF value and the morning fasting venous blood was collected. Results Before and after treatment, serum potassium and serum creatinine had no statistical significance. The levels of CRP in ACEI group and ARB group were significantly lower than those in ARB group (P <0.05). The levels of EF in ACEI group and ARB group were significantly higher than those in ARB group (P <0.05). Conclusion Valsartan can inhibit the over activation of renin - angiotensin - aldosterone system (RAAS) and improve cardiac function.